Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cimicifuga racemosa (commonly known as black cohosh) is a perennial plant native to North America and a member of the buttercup family. The root and rhizome are used in herbal preparations. It is primarily promoted as a dietary supplement for alleviating symptoms associated with menopause—such as hot flashes and sleep disturbances—and has also been used for menstrual cramps and premenstrual syndrome. Historically used by Native Americans for various ailments including musculoskeletal pain and gynecologic disorders. The mechanism of action is not fully understood; while some constituents bind to estrogen receptors with minimal estrogenic effect (and may even block some effects), other studies suggest central activity possibly involving opioid receptors or serotonin receptor modulation rather than direct hormonal action[2][3][5][7]. Key active compounds include triterpene glycosides (actein, 23-epi-26-deoxyactein), resins (cimicifugin), aromatic acid derivatives (caffeic acid), flavonoids, tannins[4][5]. Black cohosh does not contain phytoestrogens but may have weak estrogen-like effects in certain tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cimicifuga racemosa.